EU/3/18/2089

About

On 19 November 2018, orphan designation (EU/3/18/2089) was granted by the European Commission to Dystrogen Therapeutics S.A., Poland, for ex vivo fused normal allogeneic human myoblast with autologous human myoblast derived from Duchenne muscular dystrophy affected donor for the treatment of Duchenne muscular dystrophy.

Key facts

Active substance
Ex vivo fused normal allogeneic human myoblast with autologous human myoblast derived from Duchenne muscular dystrophy affected donor
Disease / condition
Treatment of Duchenne muscular dystrophy
Date of first decision
19/11/2019
Outcome
Positive
EU designation number
EU/3/18/2089

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Kasztelanska 49
60-316 Poznan
Poland
Tel. + 48 698 647 783     
E-mail: info@dystrogen.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating